$16.7
Orchard Therapeutics is a biotechnology business based in the US. Orchard Therapeutics shares (ORTX) are listed on the NASDAQ and all prices are listed in US Dollars. Orchard Therapeutics employs 166 staff and has a trailing 12-month revenue of around $21.8 million.
Our top picks for where to buy Orchard Therapeutics stock
How to buy Orchard Therapeutics stock
- Choose a stock trading platform. Use our comparison table
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – ORTX. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
Buy Orchard Therapeutics stock from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Orchard Therapeutics stock price (NASDAQ: ORTX)
Use our graph to track the performance of ORTX stocks over time.Orchard Therapeutics shares at a glance
Latest market close | $0.00 |
---|---|
52-week range | $4.80 - $16.72 |
50-day moving average | $16.44 |
200-day moving average | $10.11 |
Wall St. target price | $16.00 |
PE ratio | N/A |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | $-4.10 |
Is it a good time to buy Orchard Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Orchard Therapeutics price performance over time
Historical closes compared with the close of $0 from 2024-02-05
1 week (2024-08-25) | nan% |
---|---|
1 month (2024-08-01) | nan% |
3 months (2024-06-01) | nan% |
6 months (2024-03-01) | nan% |
1 year (2023-09-05) | -100.00% |
---|---|
2 years (2022-09-02) | -100.00% |
3 years (2021-09-03) | 2.93 |
5 years (2019-09-05) | 14.87 |
Orchard Therapeutics financials
Revenue TTM | $21.8 million |
---|---|
Gross profit TTM | $-76,515,000 |
Return on assets TTM | -29.23% |
Return on equity TTM | -71.51% |
Profit margin | 0% |
Book value | $3.53 |
Market Capitalization | $380.1 million |
TTM: trailing 12 months
Orchard Therapeutics share dividends
We're not expecting Orchard Therapeutics to pay a dividend over the next 12 months.
Have Orchard Therapeutics's shares ever split?
Orchard Therapeutics's shares were split on a 1:10 basis on 9 March 2023. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Orchard Therapeutics shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Orchard Therapeutics shares which in turn could have impacted Orchard Therapeutics's share price.
Orchard Therapeutics share price volatility
Over the last 12 months, Orchard Therapeutics's shares have ranged in value from as little as $4.8 up to $16.72. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Orchard Therapeutics's is 0.553. This would suggest that Orchard Therapeutics's shares are less volatile than average (for this exchange).
Orchard Therapeutics overview
Orchard Therapeutics plc, a gene therapy company, research, develops, and commercialize hematopoietic stem cell and gene therapies in the United Kingdom, Italy, France, and Germany. It offers OTL-200, an ex vivo autologous hematopoietic stem cell gene therapy for the treatment of patients with metachromatic leukodystrophy under the Libmeldy brand; and Strimvelis, a gammaretroviral vector-based gene therapy for the treatment of adenosine deaminase deficiency. The company's program for neurodegenerative disorders comprises clinical proof of concept-stage program, which includes OTL-203 for the treatment of mucopolysaccharidosis type I and OTL-201 for mucopolysaccharidosis type IIIA, or MPS-IIIA; and pre-clinical program, OTL-204 for the treatment of frontotemporal dementia with progranulin mutations. In addition, it develops program for immunological disorders consist of pre-clinical programs, which includes OTL-104 for Crohn's disease with mutations in the nucleotide-binding oligomerization domain-containing protein 2; and OTL-105 for the treatment of hereditary angioedema. The company was formerly known as Orchard Rx Limited. Orchard Therapeutics plc was founded in 2015 and is headquartered in London, the United Kingdom. As of January 24, 2024, Orchard Therapeutics plc operates as a subsidiary of Kyowa Kirin Co.
Frequently asked questions
What percentage of Orchard Therapeutics is owned by insiders or institutions?Currently 12.205% of Orchard Therapeutics shares are held by insiders and 103.603% by institutions. How many people work for Orchard Therapeutics?
Latest data suggests 166 work at Orchard Therapeutics. When does the fiscal year end for Orchard Therapeutics?
Orchard Therapeutics's fiscal year ends in December. Where is Orchard Therapeutics based?
Orchard Therapeutics's address is: 245 Hammersmith Road, London, United Kingdom, W6 8PW What is Orchard Therapeutics's ISIN number?
Orchard Therapeutics's international securities identification number is: US68570P1012 What is Orchard Therapeutics's CUSIP number?
Orchard Therapeutics's Committee on Uniform Securities Identification Procedures number is: 68570P101
More guides on Finder
-
Options profit calculator
Use this calculator to quickly see potential outcomes of your options trades.
-
Best options trading platforms of 2024
SoFi, Robinhood, Tastytrade, Webull, Interactive Brokers, E*TRADE, eToro and others top our list for the best options trading platforms.
-
What is a covered call?
A covered call is an options trading strategy that allows you to generate income from stocks you already own.
-
GSD Capital review 2024
A look at GSD Capital’s highlights, limitations, fees and investment strategies.
-
Today’s best brokerage account bonuses [Signup and transfer promos]
Explore the best bonuses for opening a new brokerage account.
-
10 E*TRADE competitors worth your time
Looking for a discount broker like E*TRADE that offers something different? Here are some of the top alternatives to consider.
-
Charles Schwab vs. Fidelity
Charles Schwab and Fidelity are two powerhouse trading platforms for beginner and advanced investors.
-
Interactive Brokers review 2024: Tailored trading and investing
Interactive Brokers has advanced charting tools but a high net requirement to qualify.
-
Top 15 tech stocks to invest in for 2024
Discover the top tech stocks poised to lead innovation and offer substantial growth opportunities.
-
Wealthfront review: Low-cost automated and DIY investing
Learn about Wealthfront’s automated investing tools and services to see if it’s the right platform for you.
Ask a question